Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pemvidutide - Altimmune

Next Previous
Drug Profile

Pemvidutide - Altimmune

Alternative Names: ALT-801- Altimmune; SP-1373; VPD-107

Latest Information Update: 03 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Velocity Pharmaceutical Development
  • Developer Altimmune; Velocity Pharmaceutical Development
  • Class Antifibrotics; Antihyperglycaemics; Antihyperlipidaemics; Hepatoprotectants; Obesity therapies; Peptides
  • Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alcoholic liver disorders; Alcoholism; Non-alcoholic steatohepatitis; Obesity
  • Preclinical Dyslipidaemias; Hepatic fibrosis
  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 28 May 2026 Efficacy and adverse event data from a phase IIb IMPACT trial in Non-alcoholic steatohepatitis released by Altimmune
  • 27 May 2026 Efficacy data from a phase IIb IMPACT trial in Non-alcoholic steatohepatitis released by Altimmune
  • 13 May 2026 Altimmune plans a phase III PERFORMA trial for Non-alcoholic steatohepatitis in USA in 2H 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top